Medicure (MPH) AI Stock Analysis

• Market Cap: C$11.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 10.84%
• EPS Growth: 48.57%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 10,436,313
• 10 Day Avg. Volume: 3,461
• 30 Day Avg. Volume: 2,432
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$1.00
• Price Target Upside: -12.28% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: C$1.00 ▼(-12.28% Downside)

Medicure's stock score reflects its mixed financial performance and challenging valuation. The stable balance sheet is a positive, but profitability issues and negative market momentum weigh heavily. The absence of earnings call insights and corporate events limits the analysis to financial and technical factors.

Medicure Business Overview & Revenue Model

Company Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

How the Company Makes Money

Medicure Inc. generates revenue primarily through the sale of its cardiovascular medications and related healthcare products. The company markets its products to healthcare providers, hospitals, and pharmacies, both directly and through distribution partners. Key revenue streams include direct sales of branded pharmaceutical products and licensing agreements for distribution rights. Additionally, Medicure may engage in strategic partnerships and collaborations with other pharmaceutical companies to expand its market reach and product offerings, thereby bolstering its earnings potential.

Medicure Financial Statement Overview

Summary

Medicure shows potential in revenue growth and maintaining a strong equity base, but profitability and cash flow consistency are major challenges. The company needs to focus on operational efficiencies to improve margins and stabilize cash flows for better financial health.

Income Statement

Medicure has shown some improvement in revenue over the years, but profitability remains a concern with recurring net losses. The gross profit margin is relatively stable, but negative EBIT and net profit margins indicate operational challenges. The revenue growth is slow, and efforts to improve EBITDA have not fully translated into net profitability.

Balance Sheet

The company's balance sheet shows moderate financial stability with a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests that a good portion of the assets is funded by equity, which is a positive sign of financial health.

Cash Flow

Medicure's cash flow from operations is positive, but free cash flow has been inconsistent due to capital expenditures. The operating cash flow to net income ratio is favorable, indicating strong cash generation relative to earnings. However, the free cash flow growth rate is volatile, reflecting fluctuations in investment and capital spending.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.20M	21.91M	21.69M	23.07M	21.74M	11.61M
Gross Profit	12.52M	13.09M	13.99M	16.07M	12.71M	5.13M
EBITDA	1.45M	1.54M	1.27M	3.44M	2.39M	-4.04M
Net Income	-1.35M	-1.04M	-922.00K	1.36M	-727.00K	-6.84M
Balance Sheet
Total Assets	28.41M	29.68M	28.06M	29.90M	28.41M	34.05M
Cash, Cash Equivalents and Short-Term Investments	4.74M	7.19M	6.37M	4.86M	3.69M	2.72M
Total Debt	1.09M	874.00K	544.00K	849.00K	1.17M	1.45M
Total Liabilities	10.11M	8.90M	8.16M	8.89M	10.00M	14.91M
Stockholders Equity	18.31M	20.78M	19.90M	21.00M	18.41M	19.15M
Cash Flow
Free Cash Flow	918.00K	638.00K	1.81M	1.52M	3.17M	-2.24M
Operating Cash Flow	1.47M	1.38M	2.08M	1.83M	3.99M	-2.24M
Investing Cash Flow	-2.73M	-739.00K	-270.00K	-310.00K	-2.69M	-7.24M
Financing Cash Flow	-406.00K	-370.00K	-297.00K	-355.00K	-316.00K	-766.00K

Medicure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MPH, the sentiment is Positive. The current price of 1.14 is above the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.14, and above the 200-day MA of 0.97, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 51.12 is Neutral, neither overbought nor oversold. The STOCH value of 28.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MPH.

Medicure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TH	61 Neutral	210.13M	-16.58	32.79%	―	5.24%	-7.99%
MDP	60 Neutral	95.48M	71.29	1.52%	―	0.03%	-17.30%
CTX	53 Neutral	8.58M	-6.51	-17.37%	―	20.33%	53.93%
MPH	51 Neutral	C$11.48M	―	-7.15%	―	10.84%	48.57%
RVV	46 Neutral	6.28M	-1.56	0.00%	―	0.00%	15.79%
MVMD	35 Underperform	5.29M	-0.71	0.00%	―	-46.59%	9.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medicure Corporate Events

Medicure Inc. Reports Increased Revenue and Improved EBITDA for Q2 2025

Medicure Inc. reported financial results for the quarter ended June 30, 2025, with total net revenue increasing to $6.7 million from $5.2 million in the previous year. The company saw a rise in revenue from its Marley Drug business and increased sales of ZYPITAMAG® through both insured and pharmacy channels. Despite a net loss of $786,000, the company’s adjusted EBITDA improved significantly, reflecting operational efficiencies and strategic acquisitions of Gateway and West Olympia Pharmacies. These results underscore Medicure’s commitment to expanding its market presence and enhancing shareholder value.

The most recent analyst rating on (TSE:MPH) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Medicure stock, see the TSE:MPH Stock Forecast page.

Medicure Inc. to Announce Q2 2025 Financial Results

Medicure Inc. announced it will present its financial results for the quarter ended June 30, 2025, via a conference call on August 21, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

Medicure Completes Acquisition of West Olympia Pharmacy

Medicure Inc. has completed the acquisition of West Olympia Pharmacy, aligning with its strategic plan to expand its direct-to-consumer pharmacy business. This acquisition, along with the previous acquisition of Gateway Medical Pharmacy, is expected to add approximately $10 million in additional annual net revenue, enhancing the company’s pharmacy business and strengthening sales of its marketed products.